MONTHLY INTRAVITREAL INFLIXIMAB IN BEHÇET'S DISEASE ACTIVE POSTERIOR UVEITIS
| Autor: | Abdussalam M Abdullatif, Mahmoud Soliman, Gaafar Ragab, Mostafa M Hamza, Mohammad Hussein Refaat, Tamer A. Macky, Mohamed-Sameh H El-Agha |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Visual acuity genetic structures Exacerbation Visual Acuity Pilot Projects Behcet's disease 030204 cardiovascular system & hematology Young Adult 03 medical and health sciences 0302 clinical medicine Ophthalmology 0502 economics and business medicine Humans In patient Prospective Studies Survival analysis Dose-Response Relationship Drug business.industry Behcet Syndrome 05 social sciences Uveitis Posterior General Medicine medicine.disease Infliximab eye diseases Treatment Outcome Posterior uveitis Intravitreal Injections Female Tumor Necrosis Factor Inhibitors 050211 marketing sense organs Long term safety medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | Retina. 41:1739-1747 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0000000000003095 |
| Popis: | PURPOSE To study the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease. METHODS This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1 mg/0.05 mL) for 22 eyes of 16 patients with active posterior uveitis in Behcet's disease. Control of inflammation and visual outcomes were assessed, and ocular complications were monitored during the study period. RESULTS Successful treatment was achieved in 7 eyes (35%), and failure was encountered in 13 eyes (65%). Only seven eyes of six patients (35%) had completed the study and achieved complete resolution of inflammation with improved best-corrected visual acuity and no complications. Failure was either because of inability to control the inflammation in nine eyes (45%) or development of exacerbation of inflammation in four eyes (20%). Four eyes developed severe immunological reaction from the drug after first (n = 1), second (n = 2), and third (n = 1) injections and had to discontinue the injections. Kaplan-Meier survival analysis showed that the mean estimated time to failure was 3.3 ± 0.2 months, and all failed eyes required revision of their systemic immunotherapy to control the ocular inflammation. CONCLUSION Intravitreal infliximab for active posterior uveitis in Behcet's disease was associated with a high complication rate and failure to control inflammation in most eyes. It should not be considered a substitute to systemic therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|